Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised over RMB 100 million (USD 13.8 million) in a pre-Series B financing round. The funds will be allocated to support product iteration and global development initiatives over the next four years, marking a significant step forward for the company.
Company Background and Founding Team
Qihan Biotech, founded in 2017, is an innovative biotech company with a strong academic foundation. It was established by Professor Yang Luhan, the leader of the Harvard University xenotransplantation project, and George Church, a renowned Harvard geneticist and professor, who is also an academician of the American Academy of Sciences and Engineering. This collaboration between distinguished academics and industry professionals positions Qihan Biotech at the forefront of xenotransplantation research and development.
Clinical Approval and Product Development
The company has obtained tacit clinical approval from the National Medical Products Administration (NMPA) for its product, which is heralded as the first gene-editing induced pluripotent stem cell (iPSC) derived cell therapy to achieve this milestone in China. This approval is a testament to Qihan Biotech’s commitment to advancing xenotransplantation technologies and bringing innovative treatments to patients in need.
Global Development and Future Outlook
With the proceeds from the pre-Series B financing round, Qihan Biotech is poised to accelerate its global development efforts. The company’s focus on product iteration and expansion into international markets reflects its ambition to become a global leader in xenotransplantation and cell therapy solutions.-Fineline Info & Tech
